Pfizer
Long

Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (t

165
PFE: Pfizer Inc.
2020-11-06 06:45:00
Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.